VAERS Explorer
Back to explore

Report #2895551

Received May 6, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
0.5 yrs
State
TX
Recovered
Unknown
Vaccinated
Apr 17, 2026
Onset
Apr 17, 2026
Days to onset
0
Hospital days

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
HIBVHIB (ACTHIB)SANOFI PASTEURUNKUK433ADIM / LL

Symptoms (2)

No adverse eventProduct preparation issue

Symptom narrative

gave the ACT-HIB vaccine with a diluent from a Merck vaccine,with no reported adverse event; Initial information regarding this unsolicited valid non-serious case, was received on 20-Apr-2026 from via nurse (healthcare professional). This case involves a 6-month-old female patient to whom the haemophilus type B (HIB) vaccine (ACT-HIB) was given with a diluent from a Merck vaccine, with no reported adverse event. The patient's past medical history, past drugs, and family history were not provided. Concomitant medication(s) included diphtheria vaccine toxoid, hepatitis B vaccine rHBsAg (yeast), pertussis vaccine acellular 3-component, polio vaccine inactivated 3 valent (Vero), tetanus vaccine toxoid (Pediarix), pneumococcal vaccine conjugate 20 valent (CRM197) (Pfizer PCV 20), and influenza vaccine (GSK Flu vaccine). On 17-Apr-2026, the patient received haemophilus type B (HIB) vaccine Powder and solvent for solution for injection dose 1 Strength = standard dose 0.5 ml 1x(once) intramuscularly in left thigh for immunization, vaccine was given with a diluent from a Merck vaccine, with no reported adverse event [(Product preparation issue, and latency: same day) (batch: UK433AD, expiry: 31-Aug-2027)]. Action taken: Not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.

Medical history

Comments: NONE

Other medications

Dtap hepb; Prevnar 20; Influenza vaccine